![Nick Roesen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Nick Roesen
Gründer bei The Native Antigen Co. Ltd.
Profil
Nick Roesen is the founder and currently serves as the Chief Operating Officer at The Native Antigen Co. Ltd., a company he founded in 2010.
He previously worked as a Senior Scientist at Hybrid BioSystems Ltd.
Dr. Roesen holds a doctorate degree from the University of Birmingham and an undergraduate degree from the University of Warwick.
Aktive Positionen von Nick Roesen
Unternehmen | Position | Beginn |
---|---|---|
The Native Antigen Co. Ltd.
![]() The Native Antigen Co. Ltd. Miscellaneous Commercial ServicesCommercial Services The Native Antigen Co. Ltd. develops viral vectors technologies. Its products include bacterial antigens, protozoal, and viral antigens. The company was founded by Nick Roesen and Andrew Maxwell in 2010 and is headquartered in Oxford, the United Kingdom. | Gründer | 01.01.2010 |
Ehemalige bekannte Positionen von Nick Roesen
Unternehmen | Position | Ende |
---|---|---|
Hybrid BioSystems Ltd.
![]() Hybrid BioSystems Ltd. Miscellaneous Commercial ServicesCommercial Services Hybrid is an Oxford Biotechnology Company focused on revolutionizing viral vaccines with its patented vaccine delivery technologies. Hybrid has an established and well equipped laboratory located at Cherwell Innovation Centre in Oxford shire, which houses both its corporate research facility and contract research services. Using a mixed product and platform business model it is developing its in-house lead products towards phase I/II proof of concept clinical trials as well as furthering its partnerships with leading pharmaceutical and biotechnology companies. Hybrid's experienced scientific and management team has reached this late stage of development through a highly efficient use of grant funding and revenues, together with minimal seed funding. With its unparalleled expertise in the field of viral steal thing technologies, The firm is also able to offer general and bespoke virology services, including high-quality adenovirus production and purification. Hybrid BioSystems uses iLabber electronic lab books for maximum IP protection and secure data storage. | Corporate Officer/Principal | - |
Ausbildung von Nick Roesen
University of Birmingham | Doctorate Degree |
University of Warwick | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
The Native Antigen Co. Ltd.
![]() The Native Antigen Co. Ltd. Miscellaneous Commercial ServicesCommercial Services The Native Antigen Co. Ltd. develops viral vectors technologies. Its products include bacterial antigens, protozoal, and viral antigens. The company was founded by Nick Roesen and Andrew Maxwell in 2010 and is headquartered in Oxford, the United Kingdom. | Commercial Services |
Hybrid BioSystems Ltd.
![]() Hybrid BioSystems Ltd. Miscellaneous Commercial ServicesCommercial Services Hybrid is an Oxford Biotechnology Company focused on revolutionizing viral vaccines with its patented vaccine delivery technologies. Hybrid has an established and well equipped laboratory located at Cherwell Innovation Centre in Oxford shire, which houses both its corporate research facility and contract research services. Using a mixed product and platform business model it is developing its in-house lead products towards phase I/II proof of concept clinical trials as well as furthering its partnerships with leading pharmaceutical and biotechnology companies. Hybrid's experienced scientific and management team has reached this late stage of development through a highly efficient use of grant funding and revenues, together with minimal seed funding. With its unparalleled expertise in the field of viral steal thing technologies, The firm is also able to offer general and bespoke virology services, including high-quality adenovirus production and purification. Hybrid BioSystems uses iLabber electronic lab books for maximum IP protection and secure data storage. | Commercial Services |